Switching to the oral small molecule glucagon-like peptide-1 (GLP-1) orforglipron after taking injectable GLP-1s helped patients maintain mostbut not allof their weight loss, according to a clinical trial led by Weill Cornell Medicine and NewYork-Presbyterian investigators
Follow the links above to see details on uses, dosing and side effects
Jordy AB, Albayaty M, Breitschaft A, Anderson TW, Christiansen E, Houshmand-regaard A, Manigandan E, Bkdal TA
This fragment conserves the principal bioactive domain associated with T?4s regenerative activity
Its effects on metabolic and appetite-signaling pathways continue to be an active area of cell-based research
Three to six months of jumping through hoops before you can even get the medication